Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
Circulerende tumorcellen beloftevolle biomarker bij prostaatcarcinoom
nov 2019 | Uro-oncologie